Abe S, Yoshimura H, Nagaoka S, Monden N, Kinugasa S, Nagasue N, Nakamura T
Second Department of Surgery, Shimane Medical University, Izumo, Japan.
J Am Coll Surg. 1995 Nov;181(5):389-96.
The significance of nodal metastasis in patients with early gastric cancer (ECG) (T1) is unknown. It has been suggested that patients with T2, N0 carcinoma of the stomach have a comparable survival rate to patients with T1 carcinoma of the stomach.
A retrospective review and survival analysis of 321 patients with T1/T2 adenocarcinoma of the stomach treated between 1979 to 1991 were performed.
Patients were divided into four groups: group 1, 214 patients with node-negative EGC (T1, N0); group 2, 13 patients with node-positive EGC (T1, N+); group 3, 49 patients with node-negative T2 disease (T2, N0); and group 4, 45 patients with node-positive T2 disease (T2, N+). Excluding deaths from causes other than recurrence, the survival rate for patients in groups 1 and 3 was 100 percent, in contrast to the ten-year survival rate of 72.7 percent for group 2 and 62.5 percent for group 4 patients (p < 0.001, groups 1 versus 2, groups 3 versus 4). The ten-year survival rate for patients with node-negative T2 disease (group 3, 100 percent) was significantly better than that of patients with node-positive EGC (group 2, 72.7 percent) (p < 0.001). Although differences in the survival rates were noted according to lymphatic or venous invasion and whether or not patients had EGC or T2 carcinoma, the most significant factor was lymph node invasion.
The postoperative survival rate for patients with node-positive EGC was poorer than that for those with node-negative T2 carcinomas. Reevaluation of the concept of EGC may be necessary. Post-operative chemotherapy does not appear necessary in patients with T2, N0 disease.
早期胃癌(ECG,T1期)患者发生淋巴结转移的意义尚不清楚。有人提出,胃T2、N0期癌患者的生存率与胃T1期癌患者相当。
对1979年至1991年间接受治疗的321例胃T1/T2腺癌患者进行回顾性研究和生存分析。
患者分为四组:第1组,214例淋巴结阴性的早期胃癌患者(T1,N0);第2组,13例淋巴结阳性的早期胃癌患者(T1,N+);第3组,49例淋巴结阴性的T2期疾病患者(T2,N0);第4组,45例淋巴结阳性的T2期疾病患者(T2,N+)。排除复发以外原因导致的死亡后,第1组和第3组患者的生存率为100%,相比之下,第2组患者的十年生存率为72.7%,第4组患者为62.5%(p<0.001,第1组与第2组,第3组与第4组)。淋巴结阴性的T2期疾病患者(第3组,100%)的十年生存率显著高于淋巴结阳性的早期胃癌患者(第2组,72.7%)(p<0.001)。尽管根据淋巴管或静脉侵犯情况以及患者是早期胃癌还是T2期癌,生存率存在差异,但最显著的因素是淋巴结侵犯。
淋巴结阳性的早期胃癌患者术后生存率低于淋巴结阴性的T2期癌患者。可能有必要重新评估早期胃癌的概念。T2、N0期疾病患者术后似乎无需进行化疗。